Wolfram Syndrome — progressive neurodegeneration beginning with childhood diabetes and optic atrophy, where early molecular diagnosis enables ER-stress-targeted clinical trials that could alter the disease trajectory.
Whole genome sequencing identifies all WFS1 variants — distinguishing Wolfram syndrome from isolated type 1 diabetes in children, and enabling enrollment in emerging therapies targeting the endoplasmic reticulum stress pathway.
Wolfram Syndrome
Wolfram syndrome (WS, also known as DIDMOAD: Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, Deafness) is an autosomal recessive neurodegenerative disorder caused by pathogenic variants in WFS1 (wolframin, chromosome 4p16.1) or, rarely, CISD2 (WFS2, chromosome 4q24). WFS1 encodes wolframin, an endoplasmic reticulum (ER) membrane protein critical for ER calcium homeostasis and the unfolded protein response. WFS1 deficiency produces chronic ER stress that leads to progressive β-cell apoptosis, retinal ganglion cell degeneration, and neuronal loss. Wolfram syndrome affects approximately 1 in 500,000-770,000.
Wolfram syndrome has a characteristic sequential presentation: insulin-dependent diabetes mellitus (typically diagnosed by age 6), bilateral optic atrophy (median onset age 11), diabetes insipidus (median onset age 14), and sensorineural hearing loss (median onset age 16). Progressive urinary tract complications (neurogenic bladder, hydroureteronephrosis), cerebellar ataxia, and brainstem neurodegeneration follow. Historically, median survival was approximately 30 years, with respiratory failure from brainstem atrophy as the most common cause of death.
The identification of ER stress as the central disease mechanism has opened therapeutic avenues. Clinical trials are evaluating 4-phenylbutyrate (a chemical chaperone that reduces ER stress), GLP-1 receptor agonists (which may enhance β-cell survival through ER stress modulation), and dantrolene (which modulates ER calcium). Early molecular WFS1 diagnosis — ideally at the time of childhood diabetes onset — enables trial enrollment before neurodegeneration becomes advanced, and distinguishes Wolfram from isolated type 1 diabetes, which has fundamentally different management and prognosis.
Any child diagnosed with diabetes mellitus before age 10 who subsequently develops optic atrophy should have immediate WFS1 molecular testing — Wolfram syndrome is frequently misdiagnosed as type 1 diabetes for years.
Wolfram syndrome is misdiagnosed as type 1 diabetes for years because juvenile diabetes is the first manifestation. Molecular WFS1 diagnosis before optic atrophy onset enables clinical trial enrollment during the optimal treatment window.
ER-stress-targeted clinical trials are underway — but enrollment requires confirmed WFS1 molecular diagnosis before advanced neurodegeneration
Chemical chaperone and GLP-1 agonist trials for Wolfram syndrome are enrolling patients with confirmed WFS1 variants and preserved neurological function. Once cerebellar atrophy and brainstem degeneration are established, these therapies may no longer be able to alter the disease course. Each year of delayed molecular diagnosis — while the patient is managed as 'type 1 diabetes' — is a year of continuing neurodegeneration that narrows the clinical trial treatment window.
Distinguishing Wolfram from type 1 diabetes changes the entire management trajectory — including psychiatric monitoring for depression and suicidality
Wolfram syndrome has elevated rates of psychiatric morbidity — depression, anxiety, and suicidality — that are both organic (neurodegeneration-related) and reactive (progressive disability in adolescents and young adults). This psychiatric risk requires proactive monitoring that standard type 1 diabetes management does not include. Additionally, Wolfram diabetes may not require the same intensive insulin regimen as type 1 (residual β-cell function may be present longer), and the progressive multisystem nature of Wolfram requires coordinated subspecialty care that isolated diabetes management does not trigger.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Wolfram Syndrome and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
